<DOC>
	<DOC>NCT02687542</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations</brief_title>
	<detailed_description>The study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 198 subjects will be randomized to 5 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Females of nonchildbearing potential and/or male subjects between the ages of 45 and 85 years, inclusive. Clinical diagnosis of Parkinson's disease. Able to refrain from any Parkinson's disease medication not permitted by the protocol. History or presence of atypical Parkinsonian syndrome. History of surgical intervention for Parkinson's disease. Severe acute or chronic medical or psychiatric condition or laboratory abnormality. Any condition possibly affecting drug absorption. Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>Motor Fluctuation</keyword>
</DOC>